Company intelligence / Profile preview

ASN Product Development

New Jersey, United States

Ownership: Private
Development stage: Other

Overview

ASN008 showed promising efficacy in pruritus associated with atopic dermatitis and is a Phase 2-ready topical therapy; Gusacitinib demonstrated significant improvement and is Phase 3-ready for chronic hand eczema; ASN011, a dual JAK/SYK inhibitor, was discontinued at preclinical.

Therapeutic areas: ImmunologyDermatology
Modalities: Small moleculetopical sodium channel blockerdual JAK/SYK inhibitor
Industry: Biotech

Partnerships

TrialSpark (acquired portfolio assets)Libertas Bio (spinout recipient company)Erasca (for oncology assets, parent company context)

Beyond the preview

Go deeper on ASN Product Development.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ASN Product Development.

Explore the full profile